Findlay Park Partners LLP Lowers Stock Position in Becton, Dickinson and Company $BDX

Findlay Park Partners LLP cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.3% in the 2nd quarter, HoldingsChannel reports. The firm owned 951,200 shares of the medical instruments supplier’s stock after selling 32,300 shares during the period. Becton, Dickinson and Company makes up 1.9% of Findlay Park Partners LLP’s portfolio, making the stock its 27th biggest position. Findlay Park Partners LLP’s holdings in Becton, Dickinson and Company were worth $143,945,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in BDX. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company during the third quarter valued at about $25,000. SHP Wealth Management purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth about $26,000. Prosperity Bancshares Inc purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter worth about $29,000. WPG Advisers LLC increased its position in shares of Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 61 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at about $32,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research note on Monday, July 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Royal Bank Of Canada boosted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a report on Thursday, August 13th. Barclays upped their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and an average target price of $185.67.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 11,779 shares of company stock valued at $1,974,669 in the last quarter. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Up 2.3%

Shares of BDX stock opened at $191.95 on Friday. The business has a 50-day moving average of $161.58 and a 200 day moving average of $161.13. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $192.30. The stock has a market capitalization of $52.89 billion, a PE ratio of 57.82, a P/E/G ratio of 13.53 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.